Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Gilead Sciences has licensed its spleen tyrosine kinase (SYK) inhibitors to the oncology-focused biotech firm Kronos Bio. The collection of small molecules includes entospletinib, which has already gone through multiple Phase II studies in blood cancers, and lanraplenib, which has completed Phase II trials in lupus and other autoimmune diseases. Kronos CEO Norbert Bischofberger is very familiar with the compound portfolio, having previously led R&D at Gilead. Kronos was founded in 2017 and was one of C&EN’s 10 Start-Ups to Watch in 2018.
This article has been sent to the following recipient: